Articles and Videos
Loading...
June 22, 2022
InMed Pharmaceuticals publicizes new peer-reviewed study
New academic journal spotlights potential for rare cannabinoids to treat skin conditions Read full article via Mugglehead Magazine. Excerpt: Less popular cannabinoids such as tetrahydrocannabivarin...
June 17, 2022
Benzinga All Access: Guest Speaker Shane Johnson, BayMedica GM
Dr. Shane Johnson, SVP and GM of BayMedica, InMed's subsidiary, joins Benzinga's All Access Conference on June 17, 2022. Dr. Johnson talks about how manufacturing...
Source:
Benzinga All Access
June 14, 2022
Scientific study on the biological activity of rare cannabinoids and their potential role on skin conditions published in peer-reviewed article
A peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been published in the International Journal of Molecular Sciences....
May 17, 2022
The Dales Report: InMed Pharmaceuticals: Commercializing The Development Of Rare Cannabinoids For The Wellness Market
Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, about the rare cannabinoid market and being able to manufacture rare cannabinoids like...
April 28, 2022
Edison: Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids
InMed featured in this article about the different cannabinoid manufacturing technologies that are shaping the industry. The article by Edison also talks about the cannabinoid...
April 28, 2022
Fly exclusive interview with CEO Eric Adams
Leading digital financial news publisher "The Fly" gets an update on the launch of InMed's rare cannabinoid products and progress of our programs from CEO Eric A....